Antioxidants for Treatment of Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis
Authors:
- 13 June 2022
- journal article
- review article
- Published by S. Karger AG in European Neurology
- Vol. 85 (5) , 377-388
Abstract
Introduction: Increasing evidence has shown that oxidative stress is involved in the pathogenesis of Duchenne muscular dystrophy (DMD). Oxidative stress impairs muscle function, reduces regenerative capacity, and leads to atrophy and muscle weakness. The present study aimed to evaluate the effectiveness and safety of antioxidants in treatment of DMD patients. Methods: Medline, Embase, EBSCOhost, and Cochrane Library databases were searched using relevant keywords regarding DMD and antioxidants. The risk of bias for all included studies was assessed using the Cochrane risk of bias tool. The effectiveness of antioxidants in improving pulmonary function and muscle strength in DMD patients and their rate of adverse events was evaluated by meta-analysis. Results: A total of nine eligible studies were identified. Among these, two studies involving 85 patients compared idebenone with placebo. Pooled data showed a significant improvement in pulmonary function after idebenone treatment. Flavonoids- and omega 3-based compounds (FLAVOMEGA) significantly improved muscle strength. Two studies evaluated coenzyme Q10 (CoQ10) and reported clinical improvement in physical activity. The remaining four studies evaluated pentoxifylline, superoxide dismutase, vitamin E combination with penicillamine and penicillamine alone, respectively, and found no significant differences between the intervention and placebo groups, measured by pulmonary function, muscle strength, movement function, or quality of life. Most adverse events were mild, while the rates of dropout and serious adverse events were low with respect to antioxidants. Conclusions: Idebenone appeared to be safe and effective in improving pulmonary function in DMD patients, while pentoxifylline, superoxide dismutase, penicillamine, or a combination of vitamin E with penicillamine did not show a significant therapeutic effect. CoQ10 and FLAVOMEGA might be beneficial in improving muscle strength or physical activity in DMD patients. However, additional trials with more participants are warranted in the future.Keywords
This publication has 14 references indexed in Scilit:
- Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophyPediatric Pulmonology, 2012
- Contribution of oxidative stress to pathology in diaphragm and limb muscles with Duchenne muscular dystrophyJournal of Muscle Research and Cell Motility, 2012
- Quantitative evaluation of the beneficial effects in the mdx mouse of epigallocatechin gallate, an antioxidant polyphenol from green teaHistochemistry and Cell Biology, 2012
- Immune‐Mediated Mechanisms Potentially Regulate the Disease Time‐Course of Duchenne Muscular Dystrophy and Provide Targets for Therapeutic InterventionPM&R, 2009
- POTENTIAL ROLE OF NITRIC OXIDE IN CONTRACTION‐STIMULATED GLUCOSE UPTAKE AND MITOCHONDRIAL BIOGENESIS IN SKELETAL MUSCLEClinical and Experimental Pharmacology and Physiology, 2008
- MUSCLE DAMAGE IN MDX (DYSTROPHIC) MICE: ROLE OF CALCIUM AND REACTIVE OXYGEN SPECIESClinical and Experimental Pharmacology and Physiology, 2006
- Do immune cells promote the pathology of dystrophin-deficient myopathies?Neuromuscular Disorders, 2001
- Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophiesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1995
- 1H-Nuclear magnetic resonance study of the oxidation/reduction chemistry of penicillamine in intact human erythrocytesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1990
- Treatment of Duchenne's Muscular Dystrophy With PenicillamineArchives of Neurology, 1979